PharmaMar and Boryung Pharm sign a licensing agreement for Aplidin® (plitidepsin) in Korea.
Nuevolution Announces Strategic Collaboration with Amgen in Oncology and Neuroscience.
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy.
TRACON Pharmaceuticals Announces a Strategic Licensing Collaboration for Two Janssen Oncology Assets and a $5 Million Equity Investment from Johnson & Johnson Innovation – JJDC, Inc.
4SC sells immunology portfolio to Immunic
LEO Pharma enters biologics through strategic partnership with AstraZeneca.
AFFiRiS AG successfully raises €10m equity financing
Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology.
4SC enters into licensing and development partnership with Link Health for the cancer compound 4SC 205 in China.
PharmaMar and Specialised Therapeutics Asia sign licensing and marketing agreement for APLIDIN® (plitidepsin) covering several Asian countries.